Predictive methods for efficacy of house dust mite subcutaneous immunotherapy in allergic rhinitis patients: a prospective study in a Chinese population

2020 ◽  
Vol 10 (3) ◽  
pp. 314-319 ◽  
Author(s):  
Zhuofu Liu ◽  
Hanyu Lu ◽  
Xian Feng ◽  
Li Hu ◽  
Jingjing Wang ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Prospective Study ◽  
House Dust ◽  
House Dust Mite ◽  
Chinese Population ◽  
Subcutaneous Immunotherapy ◽  
Predictive Methods ◽  
Dust Mite ◽  
A Prospective Study

scholarly journals Long-term effects of allergen-specific subcutaneous immunotherapy for house dust mite induced allergic rhinitis

2018 ◽  
Vol 132 (7) ◽  
pp. 665-665
Author(s):  
P Karthikeyan ◽  
D T Pulimoottil ◽  
R Sankar
Keyword(s):  
Allergic Rhinitis ◽  
House Dust ◽  
House Dust Mite ◽  
Subcutaneous Immunotherapy ◽  
Long Term Effects ◽  
Dust Mite

Long-term effects of allergen-specific subcutaneous immunotherapy for house dust mite induced allergic rhinitis

2017 ◽  
Vol 131 (11) ◽  
pp. 997-1001 ◽  
Author(s):  
E Sahin ◽  
D Dizdar ◽  
M E Dinc ◽  
A A Cirik
Keyword(s):  
Allergic Rhinitis ◽  
House Dust ◽  
House Dust Mite ◽  
Specific Immunotherapy ◽  
Subcutaneous Immunotherapy ◽  
Long Term Effects ◽  
Allergen Specific Immunotherapy ◽  
Dust Mite ◽  
Symptom Scores

AbstractBackground:Allergic rhinitis is strongly associated with the presence of house dust mites. This study investigated the long-term effects of allergen-specific immunotherapy. Allergen-specific immunotherapy was applied over three years. The study was based on a 10-year follow up of patients with allergic rhinitis.Methods:The study was conducted between 2001 and 2015. Skin prick test results and symptom scores were evaluated before (26 patients) and after 3 years (20 patients) of allergen-specific immunotherapy (using data from a previously published study), and 10 years after allergen-specific immunotherapy had ended (20 of 26 patients).Results:The symptom scores before allergen-specific immunotherapy were significantly higher than those obtained after 3 years of allergen-specific immunotherapy and 10 years after allergen-specific immunotherapy (p < 0.0175). There were no significant differences between the scores obtained at 3 years and 10 years after allergen-specific immunotherapy (p > 0.0175).Conclusion:Subcutaneous immunotherapy is an effective treatment for house dust mite induced allergic rhinitis.

scholarly journals Dropouts From Sublingual Immunotherapy and the Transition to Subcutaneous Immunotherapy in House Dust Mite-Sensitized Allergic Rhinitis Patients

2022 ◽  
Vol 2 ◽  
Author(s):  
Huan Chen ◽  
Guo-qing Gong ◽  
Mei Ding ◽  
Xiang Dong ◽  
Yuan-li Sun ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Allergic Asthma ◽  
House Dust ◽  
House Dust Mite ◽  
Sublingual Immunotherapy ◽  
Dropout Rates ◽  
Subcutaneous Immunotherapy ◽  
Transition Rates ◽  
Dust Mite

Purpose: Both subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) are effective in reducing symptoms and medication scores and inducing long-term efficacy in patients with allergic rhinitis (AR). However, SLIT has been associated with poor patient adherence. This study investigates the factors impacting dropout rates from SLIT in house dust mite (HDM)-sensitized AR patients.Methods: A retrospective study was performed to analyze dropout rates and reasons in AR patients receiving Dermatophagoides farinae (Der f) SLIT with a follow-up period of 2 years.Results: A total of 719 HDM-sensitized AR patients received Der f-SLIT. Dropout rates increased with time and most occurred after 1 year of SLIT. By month 24, 654 (91%) patients had discontinued SLIT. The dropout rates by month 24 were 100, 90.1, and 91.1% in children &lt;5 years old, children aged 5–18 years old, and adults ≥ 18 years old, respectively. Combination with allergic asthma and mono- or multi-sensitization to other aeroallergens did not affect the dropout rates. The most common self-reported reasons for dropouts were refusal of continuation, dissatisfaction with the efficacy, transition to SCIT, and adverse effects. Refusal of continuation increased with age, whereas transition to SCIT decreased with age. Ninety-seven cases transitioned from SLIT to SCIT, and the transition rates increased with time. Comorbid allergic asthma did not affect the transition rates. However, multi-sensitization was associated with a slightly higher rate of transition to SCIT. The most common reason for the transition was dissatisfaction with the efficacy (54.6%), which was only reported by patients older than 5 years. For children who began SLIT at younger than 5 years old, the most common reason (81.2%) for transition was age reaching 5 years.Conclusions: HDM-SLIT has a very high dropout rate, which is mainly due to refusal of continuation and dissatisfaction with the efficacy. Transitioning from SLIT to SCIT may help keep these patients on AIT and thus increase adherence and long-term efficacy.

scholarly journals Sublingual immunotherapy in patients with house dust mite allergic rhinitis: prospective study of clinical outcomes over a two-year period – CORRIGENDUM

2017 ◽  
Vol 131 (2) ◽  
pp. 187-187
Author(s):  
J Y Soh ◽  
M Thalayasingam ◽  
S Ong ◽  
E X L Loo ◽  
L P Shek ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Prospective Study ◽  
Clinical Outcomes ◽  
House Dust ◽  
House Dust Mite ◽  
Sublingual Immunotherapy ◽  
Dust Mite

scholarly journals Genetic variants in Hippo pathway genes are associated with house dust mite‐induced allergic rhinitis in a Chinese population

2021 ◽  
Vol 11 (10) ◽  
Author(s):  
Min Chen ◽  
Rui Zheng ◽  
Fei Li ◽  
Jun‐Yi Xin ◽  
Si‐Lu Chen ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
House Dust ◽  
House Dust Mite ◽  
Genetic Variants ◽  
Chinese Population ◽  
Hippo Pathway ◽  
Dust Mite

scholarly journals Long-term safety of subcutaneous immunotherapy with TO-204 in Japanese patients with house dust mite-induced allergic rhinitis and allergic bronchial asthma: Multicenter, open label clinical trial

2018 ◽  
Vol 67 (3) ◽  
pp. 347-356 ◽  
Author(s):  
Takao Fujisawa ◽  
Terufumi Shimoda ◽  
Keisuke Masuyama ◽  
Kimihiro Okubo ◽  
Kohei Honda ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Allergic Rhinitis ◽  
Bronchial Asthma ◽  
House Dust ◽  
House Dust Mite ◽  
Japanese Patients ◽  
Subcutaneous Immunotherapy ◽  
Open Label ◽  
Dust Mite

The changes in different symptom scores during subcutaneous immunotherapy in Chinese house dust mite allergic patients: a two-year, observational study

2019 ◽  
Vol 133 (03) ◽  
pp. 213-219
Author(s):  
Y Tu ◽  
H Zhang ◽  
L Zhao ◽  
P Jin ◽  
X Zi ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
House Dust ◽  
House Dust Mite ◽  
Analogue Scale ◽  
Asthma Symptom ◽  
Nasal Symptom ◽  
Subcutaneous Immunotherapy ◽  
Medication Score ◽  
Dust Mite ◽  
Symptom Scores

AbstractBackgroundSubcutaneous immunotherapy is an effective and safe treatment for allergic rhinitis and allergic asthma. Different symptom scores are used to evaluate the efficacy of subcutaneous immunotherapy in clinical trials.MethodA total of 58 allergic rhinitis patients sensitised to house dust mites, with or without mild asthma, were included. Symptom score, medication score, visual analogue scale score and quality of life were assessed before and after 6, 12 and 24 months of subcutaneous immunotherapy.ResultsAfter two years of subcutaneous immunotherapy, asthma symptom scores nearly reached zero, whereas the scores remained higher for nasal symptoms. The changes in asthma symptom scores were markedly different (p &lt; 0.05) and occurred faster than the changes in nasal symptom scores when compared between monosensitised and polysensitised groups. Significant reductions in visual analogue scale score and medication score were demonstrated after subcutaneous immunotherapy.ConclusionTwo-year subcutaneous immunotherapy with house dust mite vaccine is an effective treatment for both monosensitised and polysensitised allergic patients. The changes in asthma symptom scores were markedly different and occurred quicker than the changes in nasal symptom scores in Chinese house dust mite allergic patients.

Sign in / Sign up

Export Citation Format

Share Document